MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New combo before transplant aims to beat High-Risk leukemia
Disease control TerminatedThis study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that kills can…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug combo aims to tame stem cell Transplant's worst side effect
Disease control OngoingThis study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or seve…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control OngoingThis early-stage trial tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The study combines these modified cells with chemotherapy …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemias
Disease control OngoingThis early-phase study tests a new type of immunotherapy for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, wh…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC